Recursion Pharmaceuticals RXRX
$2.45 −$0.27 (-9.93%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $2.51 +2.39%
Open$2.63
Prev close$2.72
Day range$2.44 – $2.76
Volume29.88M
Market cap$1.53B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$18.06M+262.3% YoY
Operating profit-$123.18M+28.5% YoY
Net profit-$119.04M+26.6% YoY
Diluted EPS-$0.22+38.9% YoY
Free cash flow-$77.81M+33.8% YoY
Operating cash flow-$77.41M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin27.9%
Operating margin-738.7%
Net margin-709.8%
Return on equity-48.7%
Return on assets-36.3%
Return on invested capital-47.1%
Current ratio5.01
Liabilities / assets25.9%
Cash & investments$549.85M
Total debt$62.44M
Net cash (debt)$487.42M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $18.55M | $7.67M | $6.47M | $74.68M | $35.54M |
| Total Operating Revenue | $18.06M | $7.30M | $6.30M | $74.26M | $35.35M |
| Cost of Revenue | $10.05M | $11.49M | $12.49M | $70.95M | $14.28M |
| Gross Profit | $8.01M | -$4.19M | -$6.19M | $3.30M | $21.08M |
| Operating Expense | $131.19M | $130.78M | $122.32M | $651.44M | $129.41M |
| Selling and Admin Expenses | $32.56M | $41.53M | $34.59M | $176.59M | $33.66M |
| -General & Admin Expense | $32.56M | $41.53M | $34.59M | $176.59M | $33.66M |
| Research & Development | $99.12M | $89.61M | $87.90M | $475.27M | $95.94M |
| Other Operating Expenses | -$497,000.00 | -$367,000.00 | -$171,000.00 | -$425,000.00 | -$187,000.00 |
| Operating Profit | -$123.18M | -$134.97M | -$128.51M | -$648.13M | -$108.33M |
| Net Non-Operating Interest Income (Expense) | $4.55M | $5.00M | $5.61M | $20.98M | $6.26M |
| Non-Operating Interest Income | $4.82M | $5.31M | $5.96M | $22.79M | $6.25M |
| Non-Operating Interest Expense | $266,000.00 | $309,000.00 | $350,000.00 | $1.81M | -$11,000.00 |
| Other Income (Expense) | -$385,000.00 | -$1.04M | $784,000.00 | -$17.74M | -$6.03M |
| Other Non-Operating Income (Expenses) | -$385,000.00 | -$1.04M | $784,000.00 | -$17.74M | -$6.03M |
| Pretax Profit | -$119.01M | -$131.01M | -$122.11M | -$644.90M | -$108.10M |
| Tax | $25,000.00 | -$1,000.00 | -$4.60M | -$136,000.00 | $20,000.00 |
| Net Profit | -$119.04M | -$131.01M | -$117.50M | -$644.76M | -$108.12M |
| Profit from Continuing Operations | -$119.04M | -$131.01M | -$117.50M | -$644.76M | -$108.12M |
| Net Income to Parent Company | -$119.04M | -$131.01M | -$117.50M | -$644.76M | -$108.12M |
| Net Income to Common Stockholders | -$119.04M | -$131.01M | -$117.50M | -$644.76M | -$108.12M |
| Basic EPS | -$0.22 | -$0.25 | -$0.22 | -$1.44 | -$0.21 |
| Diluted EPS | -$0.22 | -$0.25 | -$0.22 | -$1.44 | -$0.21 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.22B | $1.21B | $1.34B | $1.47B | $1.47B |
| Total Current Assets | $616.02M | $603.46M | $709.56M | $812.85M | $812.85M |
| Cash and Cash Equivalents & Short-Term Investments | $549.85M | $545.68M | $654.47M | $743.29M | $743.29M |
| -Cash and Cash Equivalents | $549.85M | $545.68M | $654.47M | $743.29M | $743.29M |
| Receivables | $34.07M | $14.39M | $13.59M | $24.65M | $24.65M |
| -Other Receivables | $34.07M | $14.39M | $13.59M | $24.65M | $24.65M |
| Prepaid Assets | $2.88M | $8.68M | $11.74M | $11.74M | $11.74M |
| Restricted Cash | $6.66M | $5.39M | $5.51M | $4.59M | $4.59M |
| Other Current Assets | $22.56M | $29.32M | $24.25M | $28.57M | $28.57M |
| Total Non-Current Assets | $605.69M | $609.21M | $629.97M | $661.29M | $661.29M |
| Net PPE | $152.70M | $147.07M | $157.32M | $169.48M | $169.48M |
| -Gross PPE | $152.70M | $147.07M | $157.32M | $258.69M | $258.69M |
| Goodwill and Other Intangible Assets | $434.39M | $443.24M | $454.24M | $472.06M | $472.06M |
| -Goodwill | $160.71M | $160.35M | $160.17M | $162.16M | $162.16M |
| -Other Intangible Assets | $273.68M | $282.89M | $294.07M | $309.90M | $309.90M |
| Non-Current Deferred Assets | $957,000.00 | $957,000.00 | $957,000.00 | $957,000.00 | $957,000.00 |
| Other Non-Current Assets | $17.65M | $17.94M | $17.44M | $18.79M | $18.79M |
| Total Liabilities | $315.90M | $297.67M | $314.75M | $343.27M | $343.27M |
| Total Current Liabilities | $122.92M | $119.89M | $129.70M | $147.71M | $147.71M |
| Payables | $20.37M | $16.23M | $20.35M | $18.12M | $18.12M |
| -Accounts Payable | $16.38M | $12.67M | $20.35M | $18.12M | $18.12M |
| -Total Tax Payable | $3.99M | $3.56M | – | – | – |
| Current Accrued Expenses | $34.43M | $33.51M | $39.64M | $38.46M | $38.46M |
| Short-Term Debt and Capital Lease Obligation | $24.07M | $22.69M | $22.35M | $21.75M | $21.75M |
| -Current Debt | $11.81M | $9.44M | $9.27M | $9.09M | $9.09M |
| -Current Capital Lease Obligation | $12.26M | $13.25M | $13.09M | $12.66M | $12.66M |
| Current Deferred Liabilities | $18.97M | $29.50M | $32.79M | $37.61M | $37.61M |
| Total Non-Current Liabilities | $192.98M | $177.78M | $185.05M | $195.56M | $195.56M |
| Long Term Debt and Capital Lease Obligation | $50.63M | $43.95M | $50.02M | $56.21M | $56.21M |
| -Long Term Debt | $93,000.00 | $4.75M | $7.18M | $9.56M | $9.56M |
| -Long Term Capital Lease Obligation | $50.54M | $39.19M | $42.84M | $46.65M | $46.65M |
| Non-Current Deferred Liabilities | $138.39M | $131.13M | $133.01M | $137.27M | $137.27M |
| Other Non-Current Liabilities | $3.96M | $2.70M | $2.03M | $2.08M | $2.08M |
| Total Equity | $905.81M | $915.00M | $1.02B | $1.13B | $1.13B |
| Stockholders' Equity | $905.81M | $915.00M | $1.02B | $1.13B | $1.13B |
| Capital Stock | $6,000.00 | $5,000.00 | $5,000.00 | $5,000.00 | $5,000.00 |
| -Common Stock | $6,000.00 | $5,000.00 | $5,000.00 | $5,000.00 | $5,000.00 |
| Additional Paid-In Capital | $3.32B | $3.21B | $3.19B | $3.17B | $3.17B |
| Retained Earnings | -$2.44B | -$2.32B | -$2.19B | -$2.08B | -$2.08B |
| Gains/Losses Not Affecting Retained Earnings | $29.63M | $27.99M | $26.66M | $36.72M | $36.72M |
| -Accumulated Depreciation | – | – | – | -$89.21M | -$89.21M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$77.41M | -$105.95M | -$81.10M | -$371.81M | -$46.07M |
| Net cash flow from continuing operations | -$77.41M | -$105.95M | -$81.10M | -$371.81M | -$46.07M |
| Net Income from Continuing Operations | -$119.04M | -$131.01M | -$117.50M | -$644.76M | -$108.12M |
| Depreciation & Depletion & Amortization | $16.54M | $18.17M | $19.67M | $83.70M | $19.48M |
| Deferred Tax | $0.00 | -$3,000.00 | -$4.60M | – | – |
| Other Non-Cash Items | $6.28M | $5.96M | $6.92M | $53.88M | $30.43M |
| Change in Working Capital | -$4.21M | -$18.56M | -$7.81M | $13.69M | $10.68M |
| -Change in Receivables | -$13.88M | -$6.29M | $14.75M | $32.94M | -$836,000.00 |
| -Change in Prepaid Assets | $5.80M | $3.06M | $0.00 | $49.86M | $20.26M |
| -Change in Payables and Accrued Expense | $13.56M | -$3.39M | -$15.65M | -$12.35M | $1.88M |
| -Change in Other Current Liabilities | -$4.63M | -$4.64M | -$4.65M | -$19.99M | -$3.86M |
| -Change In Other Working Capital | -$5.05M | -$7.30M | -$2.25M | -$36.77M | -$6.76M |
| Net cash flow from investing | -$407,000.00 | -$1.96M | -$338,000.00 | -$16.87M | -$1.24M |
| Net Cash Flow from Continuing Investing Activities | -$407,000.00 | -$1.96M | -$338,000.00 | -$16.87M | -$1.24M |
| Net PPE Purchase and Sale | -$407,000.00 | -$44,000.00 | -$258,000.00 | -$6.47M | -$1.24M |
| Net Intangibles Purchase and Sale | $0.00 | -$1.92M | -$80,000.00 | -$2.16M | $0.00 |
| Net Business Purchase and Sale | $0.00 | $0.00 | $0.00 | -$4.44M | $0.00 |
| Net Investment Purchase and Sale | $0.00 | $0.00 | $0.00 | -$3.81M | $0.00 |
| Financing Cash Flow | $83.14M | -$1.27M | -$3.47M | $521.53M | $132.01M |
| Net Cash Flow from Continuing Financing Activities | $83.14M | -$1.27M | -$3.47M | $521.53M | $132.01M |
| Net Issuance Payments Of Debt | -$2.29M | -$2.25M | -$2.21M | -$8.43M | -$2.17M |
| Net Common Stock Issuance | $85.52M | $0.00 | $0.00 | $528.86M | $133.38M |
| Proceeds from Stock Option Exercised | -$77,000.00 | $984,000.00 | -$1.26M | $4.09M | $793,000.00 |
| Ending Cash Balance | $561.53M | $556.82M | $665.18M | $753.92M | $753.92M |
| Net Change in Cash | $5.33M | -$109.17M | -$84.91M | $132.85M | $84.69M |
| Beginning Cash Balance | $556.82M | $665.18M | $753.92M | $603.02M | $667.15M |
| Effect of Exchange Rate Changes | -$621,000.00 | $813,000.00 | -$3.83M | $18.04M | $2.09M |
| Free Cash Flow | -$77.81M | -$107.91M | -$81.44M | -$380.44M | -$47.32M |
| Gain/Loss from Continuing Operations | – | – | – | $4.50M | -$22.08M |
| Net Other Financing Charges | – | – | – | -$3.00M | $0.00 |
No comments yet — be the first to weigh in on RXRX.
Sign in to join the discussion.